Highlights for October 2017

  1. Lupin acquires Symbiomix for $150 million with $50 million upfront payment.
  2. Cadila Pharmaceuticals Ltd. and Altus Formulation Inc. announces product co-development and licensing agreement of Flexitab™ technology.
  3. Fosun Pharma has acquired approximately 74 per cent in India’s Gland Pharma at a valuation for $1.09 billion.
  4. Torrent Pharma in advanced talks to buy Unichem’s India business for INR 3,200-3,300 crore.
  5. Xynomic In-Licenses RAF Inhibitor from Boehringer in $502 Million deal.
  6. Roche taps Warp Drive to discover novel antibiotic classes in $387M pact.
  7. CytomX scores deal with Amgen worth potential $1.5bn.
  8. Smith & Nephew to acquire Rotation Medical for up to $210M.
  9. Incyte pays MacroGenics $150M for PD-1 inhibitor.
  10. MSF deal to bring generic next-gen HCV therapies to developing world.
  11. Amgen takes JV fully under its wing in $780 million swoop.
  12. Takeda And Hemoshear Therapeutics Enter Into Exclusive Drug Discovery Partnership In Liver Diseases.

For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.

 

Updates at Aagami:

  • Aagami CEO to visit India along with UK client 20-22 Nov for term sheet level meetings with Top companies
  • Aagami CEO to tour India with another client 28-30 Nov for strategic partnering with Top Indian Pharma Executives 
  • Aagami expands team to serve growing demand